Revelation Biosciences, Inc.
REVB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001810560
No open-market purchases or sales by Revelation Biosciences, Inc. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $313.2K in total; no superinvestor holds it.
Other share classesREVBW
Q2 2026 vs. Q1 2026
How the institutions holding Revelation Biosciences, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 12 | 12 | 0 |
| Shares | 499.7K | 304.3K | −195.4K (−39.1%) |
| Value | $599.8K | $313.2K | −$286.6K (−47.8%) |
New holders (3)
Institutions that held Revelation Biosciences, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 38,579 | $39.7K | 0.00% |
| HRT Financial LP | 16,978 | $17.0K | 0.00% |
| Barclays PLC | 168 | $173 | 0.00% |
Sold out (3)
Institutions that held Revelation Biosciences, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Armistice Capital, LLC | 323,241 | $387.9K |
| XTX Topco Ltd | 11,385 | $13.7K |
| UBS Group AG | 4,115 | $4.94K |